17th North American Regional ISSX Meeting (October 16

P80

Accurate Mass Imaging MALDI MS of Whole Animal Tissues to Assess the Label-Free Disposition of Drug
Sheerin K. Shahidi-Latham, Genentech Inc.; Cristine Quiason, Genentech Inc.; D. Shannon Cornett, Bruker Daltonics; Katherine A. Kellersberger, Bruker Daltonics; Brian J. Dean, Genentech Inc.

P81

Disposition of 14C-RRx-001 in Rats after A Single Intravenous Administration and in Blood from Rats, Dogs, Monkeys, and Humans
Jan Scicinski, RadioRx Inc.; Bryan Oronsky, RadioRx Inc.; William Fitch, Stanford University; Michael Taylor, NonClinical Safety Assessment; Gang Luo, Covance Laboratories Inc.; Timothy Musick, Covance Laboratories Inc.; Joseph Marini, Covance Laboratories Inc.; Chris Adams, Stanford University; Michael Schicker, Covance Laboratories Inc.; Mark Gohdes, Covance Laboratories Inc.; Don Mckenzie, Covance Laboratories Inc.; Richard Ridgewell, Covance Laboratories Inc.

P82

METABOLISM AND EXCRETION OF [¹⁴C]CRIZOTINIB IN RATS AND DOGS
Evan B. Smith, Pfizer Inc.; Lance Goulet, Pfizer Inc.; Gregory S. Walker, Pfizer Inc.; Shinji Yamazaki, Pfizer Inc.; Theodore R. Johnson, Pfizer Inc.; Deepak Dalvie, Pfizer Inc.; Bill J. Smith, Pfizer Inc.

P83

METABOLISM, EXCRETION AND PHARMACOKINETICS OF [¹⁴C]CRIZOTINIB FOLLOWING ORAL ADMINISTRATION TO HEALTHY SUBJECTS
Theodore R. Johnson, Pfizer Inc.; Lance Goulet, Pfizer Inc.; Evan B. Smith, Pfizer Inc.; Shinji Yamazaki, Pfizer Inc.; Gregory S. Walker, Pfizer Inc.; Weiwei Tan, Pfizer Inc.; Chunze Li, Pfizer Inc.; Yao Ni, Pfizer Inc.; Gabriella Bedarida, Pfizer Inc.; Nicoletta Brega, Pfizer Inc.; Deepak Dalvie, Pfizer Inc.; Bill J. Smith, Pfizer Inc.

P84

Metabolic Fate and Disposition of GSK2251052, a Novel Boron-Based Antimicrobial against Gram-Negative Bacteria, in Sprague Dawley Rats and Cynomolgus Monkeys
Liang Liu, Anacor Pharmaceuticals Inc.; Stephen Baker, Anacor Pharmaceuticals Inc.; Michael Fitzsimmons, Covance Inc.; Amber Watney, Covance Inc.; Wei Bu, Anacor Pharmaceuticals Inc.; Michael Potchoiba, Covance Inc.; Ming Qi, Covance Inc.; Michael R. K. Alley, Anacor Pharmaceuticals Inc.; Lisa Feng, Anacor Pharmaceuticals Inc.; Vincent Hernandez, Anacor Pharmaceuticals Inc.; Irwin Heyman, Anacor Pharmaceuticals Inc.; Sanjay Chanda, Anacor Pharmaceuticals Inc.

P85

Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis
Rhiannon N. Hardwick, University of Arizona; Craig D. Fisher, University of Arizona; Stephanie M. Street, University of Arizona; Mark J. Canet, University of Arizona; Nathan J. Cherrington, University of Arizona

P86

Ocular and Systemic Distribution of INO-8875, a Selective Adenosine A1 Receptor Agonist, in Rabbits by Quantitative Whole Body Autoradiography (QWBA) and Tissue Analysis
Elizabeth Prescott, Covance; Craig Struble, Covance; Jon Denissen, Covance; Norman Kim, Inotek Pharmaceuticals Corporation

P87

TISSUE DISTRIBUTION OF ⁵¹Cr-LABELED STEM CELLS AFTER INTRAVENOUS OR INTRATHECAL ADMINISTRATION IN RAT
Dragomir I. Draganov, WIL Research Laboratories, LLC; Justin Godsey, WIL Research Laboratories, LLC; Sicco Popma, WIL Research Laboratories, LLC; Terry L. Johnson, WIL Research Laboratories, LLC

P88

UGT-Catalyzed Glucuronidation: An Important Elimination Mechanism of GS-1101 (CAL-101), a Potent and Selective Inhibitor of the p110 delta Isoform of Phosphoinositide 3-kinase (PI3K delta) for Treatment of Patients With Hematologic Malignancies
Hao Chen, Gilead Sciences, Inc; Heather Webb, Gilead Sciences, Inc; Jerry Evarts, Gilead Sciences, Inc; Roger Ulrich, Gilead Sciences, Inc